Reference number(s)
1947-A

SPECIALTY GUIDELINE MANAGEMENT

NOVOSEVEN RT (coagulation factor VIIa [recombinant])

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications
1. Hemophilia A or hemophilia B with inhibitors
2. Congenital factor VII deficiency
3. Glanzmann's thrombasthenia
4. Acquired hemophilia

B. Compendial Uses
1. Acquired von Willebrand syndrome
2. Inhibitors to factor XI

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

A. Congenital Factor VII Deficiency
Indefinite authorization may be granted for treatment of congenital factor VII deficiency.

B. Hemophilia A with Inhibitors
Indefinite authorization may be granted for treatment of hemophilia A with inhibitors (see Appendix) when the inhibitor titer is ≥ 5 Bethesda units per milliliter (BU/mL).

C. Hemophilia B with Inhibitors
Indefinite authorization may be granted for treatment of hemophilia B with inhibitors (see Appendix) when the inhibitor titer is ≥ 5 Bethesda units per milliliter (BU/mL).

D. Glanzmann's Thrombasthenia
Indefinite authorization may be granted to members for treatment of Glanzmann's thrombasthenia.

E. Acquired Hemophilia
Indefinite authorization may be granted for treatment of acquired hemophilia.

F. Acquired von Willebrand Syndrome

Indefinite authorization may be granted for treatment of acquired von Willebrand syndrome when other therapies failed to control the member's condition (e.g., desmopressin or factor VIII/von Willebrand factor).

G. Inhibitors to Factor XI
Indefinite authorization may be granted for treatment of members with inhibitors to factor XI.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet ALL initial authorization criteria.

IV. APPENDIX

Appendix: Inhibitors - Bethesda Units (BU)[8]
The presence of inhibitors is confirmed by a specific blood test called the Bethesda inhibitor assay.

- High-titer inhibitors:
  - ≥ 5 BU/mL
  - Inhibitors act strongly and quickly neutralize factor
- Low-titer inhibitors:
  - < 5 BU/mL
  - Inhibitors act weakly and slowly neutralize factor

V. REFERENCES

1. NovoSeven RT [package insert]. Princeton, NJ: Novo Nordisk Inc.; October 2017.
2. National Institutes of Health. The diagnosis, evaluation, and management of von Willebrand disease. Bethesda, MD: US Dept of Health and Human Services, National Institutes of Health; 2007. NIH publication No. 08-5832
3. Tiede A, Rand J, Budde U, et al. How I treat the acquired von Willebrand syndrome. *Blood*. 2011;117(25):6777-85.
4. Federici A, Budde U, Castaman G, Rand J, Tiede A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. *Semin Thromb Hemost*. 2013;39(2):191-201.
5. Clinical Consult: CVS Caremark Clinical Programs Review. Focus on Hemophilia Agents; November 2006.
6. O'Connell NM. Factor XI deficiency – from molecular genetics to clinical management. *Blood Coagul Fibrinolysis.* 2003; 14(Suppl1):S59-S64.
7. Salomon O, Zivelin A, Livnat T. Inhibitors to factor XI in patients with severe factor XI deficiency. *Semin Hematol*. 2006;43(1 Suppl 1):S10-S12.
8. Srivastava A, Brewer A, Street A, et al. Guidelines for the management of hemophilia. *Haemophilia: The Official Journal Of The World Federation Of Hemophilia* [serial online]. January 2013;19(1):e1-e47. Available from: MEDLINE Complete, Ipswich, MA. Accessed December 9, 2017.
9. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Revised August 2017. MASAC Document # 250. Accessed December 8, 2017.
10. World Federation of Hemophilia. What are inherited platelet function disorders? http://www1.wfh.org/publication/files/pdf-1336.pdf. Accessed December 11, 2017.

11. World Federation of Hemophilia. Platelet function disorders. http://www1.wfh.org/publication/files/pdf-1147.pdf. Accessed December 11, 2017.
12. Rajpurkar M, Chitlur M, Recht M, Cooper DL. Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature. *Haemophilia*. 2014;20(4):464-471.
13. Duga S, Salomon O. Congenital factor XI deficiency: an update. *Semin Thromb Hemost*. 2013;39(6):621-631.